莫沙比利联合瑞巴派特治疗慢性萎缩性胃炎的临床效果及安全性

Clinical effect and safety of mosapride combined with rebamipide in the treatment of chronic atrophic gastritis

目的探讨莫沙比利联合瑞巴派特治疗慢性萎缩性胃炎的临床效果和安全性。方法将80例慢性萎缩性胃炎患者根据随机数字表法分为对照组(40例,莫沙比利)与观察组(40例,莫沙比利+瑞巴派特)。比较两组的临床效果。结果观察组的治疗总有效率高于对照组(P<0.05)。治疗后,两组的恶心呕吐、嗳气反酸、腹痛评分均降低,且观察组低于对照组(P<0.05)。治疗后,两组的血清CRP、PCT水平均降低,且观察组低于对照组(P<0.05)。治疗后,两组的生理、心理、环境、社会关系评分均升高,且观察组高于对照组(P<0.05)。两组患者用药后均未发生明显不良反应。结论莫沙比利联合瑞巴派特治疗慢性萎缩性胃炎的效果显著,可减轻患者的胃肠道症状及炎症反应,提高其生活质量,且安全性良好。

Objective To explore the clinical effect and safety of mosapride combined with rebamipide in the treatment of chronic atrophic gastritis.Methods A total of 80 patients with chronic atrophic gastritis were divided into control group(40 cases,mosapride)and observation group(40 cases,mosapride+rebamipide)by random number table method.The clinical effects of the two groups were compared.Results The total effective rate of treatment in the observation group was higher than that in the control group(P<0.05).After treatment,the scores of nausea and vomiting,belching acid regurgitation and abdominal pain in the two groups decreased,and those in the observation group were lower than the control group(P<0.05).After treatment,the serum CRP and PCT levels in the two groups decreased,and those in the observation group were lower than the control group(P<0.05).After treatment,the scores of physiology,psychology,environment and social relationship in the two groups increased,and those in the observation group were higher than the control group(P<0.05).No obvious adverse reactions occurred after medication in both groups.Conclusion Mosapride combined with rebamipide in the treatment of chronic atrophic gastritis has significant effect,it can reduce gastrointestinal symptoms and inflammatory reaction,improve the quality of life of patients,and has good safety.